STOCKHOLDER AGREEMENTStockholder Agreement • March 18th, 2009 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
THIS STOCKHOLDER AGREEMENT (“Agreement”) is entered into as of March 12, 2009, by and between GILEAD SCIENCES, INC., a Delaware corporation (“Parent”), and LOUIS G. LANGE (“Stockholder”).
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • March 18th, 2009 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • California
THIS AGREEMENT, made effective as of March 5, 2008 (the “Effective Date”), by and between CV Therapeutics, Inc., with principal place of business at 3172 Porter Drive, Palo Alto, CA 94304 (“CVT”), and Gilead Sciences, Inc., with principal place of business at 333 Lakeside Drive Foster City, CA 94404 (“Gilead”), to assure the protection and preservation of the confidential and proprietary nature of information to be disclosed or made available by or on behalf of the disclosing party hereunder (the “Disclosing Party”) to the receiving party hereunder (the “Receiving Party”), is entered into in connection with the following facts and circumstances:
CONFIDENTIALITY AGREEMENT AMENDMENT NO. 1Confidentiality Agreement • March 18th, 2009 • Cv Therapeutics Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT (the “Amendment No. 1”) to the Confidentiality Agreement is entered into as of February 28, 2009, by and between CV Therapeutics, Inc., with principal place of business at 3172 Porter Drive, Palo Alto, CA 94304 (“CVT”), and Gilead Sciences, Inc., with principal place of business at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”).
